IL2 and type 1 diabetes mellitus: In T1D, clinical efficacy trials are ongoing with LD-IL-2 to reduce the decline of C-peptide in newly-diagnosed patients (ITAD63 and DIABIL-2; ClinicalTrials.gov identifiers NCT03782636 and NCT02411253, respectively).